We are focused on developing differentiated products for the treatment and prevention of serious
infectious diseases. Our clinical-stage programs include INX-189 and FV-100 which are potent, orally available, antiviral
for the treatment of herpes zoster (shingles), and Aurexis
®, a humanized monoclonal antibody
for the adjunct treatment of serious
S. aureus infections. Antiviral programs in pre-clinical development
include differentiated oral compounds for the treatment of HCV. We have licensed our MSCRAMM
® protein platform technology
to Pfizer for use in the development of vaccines to prevent S.
aureus infection.
| Antiviral |
|
FV-100 (shingles)
|
 |
| INX-189 (HCV) |
 |
INX-189 (HCV) (back-up) |
 |
INX-189 (HCV) (follow-on) |
 |
| Antibacterial |
|
| Aurexis ® |
 |
| Staph vaccine |
* |
Footnotes:
* Partnered with
Pfizer